In:
International Journal of Cancer, Wiley, Vol. 147, No. 8 ( 2020-10-15), p. 2225-2238
Abstract:
What's new? Epithelial ovarian cancer (EOC) generally has an extremely poor prognosis, and new therapies are urgently needed. In this study, the authors examined a multidrug‐resistance efflux pump called MRP4, which is regulated by the Myc oncogene. They found that increased expression of MRP4 was associated with poor prognosis, and that siRNA‐mediated knockdown of MRP4 led to decreased growth, migration, and invasion of EOC cells in vitro and tumors in vivo. These results suggest that MRP4 may provide a valuable therapeutic target for certain EOC tumors.
Type of Medium:
Online Resource
ISSN:
0020-7136
,
1097-0215
Language:
English
Publisher:
Wiley
Publication Date:
2020
detail.hit.zdb_id:
218257-9
detail.hit.zdb_id:
1474822-8
Permalink